ClinicalTrials.gg
RecruitingNCT05875740Updated Oct 13, 2026

Correlation of Memory CD8+ T Cells With Sepsis Severity and Mortality: a Single-center, Unblinded, Prospective, Non-interventional, Observational Study

An observational study in Sepsis and Inflammatory Response, sponsored by Union Hospital, Tongji Medical College, Huazhong University of Science and Technology. Recruiting at 1 site in China. Open to participants aged 18 Years to 60 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-10-13.

Sponsored by Union Hospital, Tongji Medical College, Huazhong University of Science and Technology · Observational

How we know

From the registry’s dates

  • Started Sep 2023; still recruiting 3 years 2 months later.
Updated Oct 13, 2026Primary completion movedStudy completion movedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
80
Ages
18 Years to 60 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 286 studies in Sepsis with a site in China — 99 open to participants now, 106 under way, 5 of them phase 3. Sepsis · China.

Planned enrollment
123rd of 164
80 · median 180
Started
2023
with 17 others
Observational
165 of 286
51 open now
Primary completion
2026-10
later than 44 of 105 live
Registered
176th of 286
by date

Among the 286 studies in Sepsis with a site in China, this one is the 123rd largest by planned enrollment of the 164 observational ones that give a count, is one of 18 that started in 2023, is one of 165 observational ones, reaches primary completion later than 44 of the 105 other live ones, and was the 176th registered.

Sepsis

2,425 studies on the registry are indexed under Sepsis; 543 are open to participants now.

Browse Sepsis studies →

Open to participants now

99 of the 286 studies in Sepsis with a site in China are open now. Recruiting first, the newest first:

94 more — sign in →

All 99 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 319 Sepsis studies recruiting now, 212 (66%) set no upper age limit and 52 (16%) stop at 75 or younger; 67 take children under 18; 43 take healthy volunteers.

This study: 18 Years to 60 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 286 studies in Sepsis with a site in China, or all of them as a file.
02

Study summary

Sepsis is defined as a life-threatening organ dysfunction that is caused by a dysregulated host response to infection. Severe sepsis is the most common cause of death among critically ill patients in non-coronary intensive care units (ICU). Sustained excessive inflammation and immune dysfunction have been confirmed to play a key role in organ damage and early death of sepsis patients. Therefore, it is important to reduce excessive inflammatory response mediated by immune cells and pro-inflammatory cytokines in the acute phase of sepsis.

Single-cell RNA sequencing performed on both septic patients and mice suggest that changes in Tcm (CD3+ CD8+ CD44+ CD127+ CD62L+) and Tem (CD3+ CD8+ CD44+ CD127+ CD62L -) in the acute phase of sepsis may play an important role in sepsis. In addition, animal researches showed that Tcm and Tem decreased decreased continuously at 24, 48 and 72h after cecal ligation and perforation (CLP) in mice, and the adoptive transfer of Tcm , sorting from spleen of mice 24h after CLP , but not Tem improved 7-day survival rate of sepsis mice.

This observational study is aimed to investigate the quantity and proliferation of Tcm and Tem in the acute phase of sepsis and their correlation with severity level and mortality of septic patients in ICU.

03

Conditions studied

  • Sepsis
  • Inflammatory Response

Browse trials for

Keywords

  • sepsis
  • CD8+ T cell
  • central memory CD8+ T cell
  • inflammatory response
04

Who can participate

Ages eligible
18 Years to 60 Years
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

patients with sepsis defined based on Sepsis 3.0 criteria

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Patients aged 18-60 years old without restriction of gender, race, religion, creed or nationality; No sedative drugs with elimination half-life were used before inclusion in the study; Patients and/or their family members know and agree to participate in the trial.

Exclusion criteria

Exclusion Criteria:

History of solid organ or bone marrow transplantation; Diseases that may affect immune-related indicators, such as diseases such as rheumatoid arthritis and SLE, or hematological such as leukemia and lymphoma; Have received radiotherapy or chemotherapy within the past 30 days, or have received drugs (tripterygium, mycophenolate, cyclophosphamide, FK506, etc); Pregnancy or lactation; Chronic nephrosis; Severe chronic liver disease (: Grade C); alcohol or opioid dependence, mental illness, or severe cognitive impairment; Patients and/or their family members refuse to participate in the trial.

Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
80 participants (estimated)
Patient registry
No

Groups and cohorts

  • septic patients

    patients with sepsis defined based on Sepsis 3.0 criteria within 24 hours after admission

  • healthy control group

    healthy adults

06

What researchers measure

Primary outcomes

  1. Absolute number of CD8+T subsets in the peripheral blood (0 hour)

    CD3+ CD8+ CCR7+ CD127high CD62L+ CD27high CD45RA- cells,and CD3+ CD8+ CCR7- CD127- CD62L- CD27low CD45RA- cells

    Time frame: 0 hour after study inclusion

  2. Absolute number of CD8+T subsets in the peripheral blood (24 hours)

    CD3+ CD8+ CCR7+ CD127high CD62L+ CD27high CD45RA- cells,and CD3+ CD8+ CCR7- CD127- CD62L- CD27low CD45RA- cells

    Time frame: 24 hours after study inclusion

  3. Absolute number of CD8+T subsets in the peripheral blood (48 hours)

    CD3+ CD8+ CCR7+ CD127high CD62L+ CD27high CD45RA- cells,and CD3+ CD8+ CCR7- CD127- CD62L- CD27low CD45RA- cells

    Time frame: 48 hours after study inclusion

  4. Absolute number of CD8+T subsets in the peripheral blood (72 hours)

    CD3+ CD8+ CCR7+ CD127high CD62L+ CD27high CD45RA- cells,and CD3+ CD8+ CCR7- CD127- CD62L- CD27low CD45RA- cells

    Time frame: 72 hours after study inclusion

  5. proliferation of CD8+T subsets in the peripheral blood (0 hour)

    expression of Ki67 in Tcm and Tem

    Time frame: 0 hour after study inclusion

  6. proliferation of CD8+T subsets in the peripheral blood (24 hours)

    expression of Ki67 in Tcm and Tem

    Time frame: 24 hours after study inclusion

  7. proliferation of CD8+T subsets in the peripheral blood (48 hours)

    expression of Ki67 in Tcm and Tem

    Time frame: 48 hours after study inclusion

  8. proliferation of CD8+T subsets in the peripheral blood (72 hours)

    expression of Ki67 in Tcm and Tem

    Time frame: 72 hours after study inclusion

  9. ICU length of stay

    Length of stay in the ICU

    Time frame: up to 4 weeks

  10. PD-1 expression of CD8+T subsets in the peripheral blood (24 hours)

    expression of PD-1 in Tcm and Tem

    Time frame: 24 hours after study inclusion

Secondary outcomes

  1. Mechanical ventilation time after inclusion

    Patients requiring mechanical ventilation after study inclusion

    Time frame: up to 4 weeks

  2. Total hospital length of stay

    Total length of hospital stay

    Time frame: up to 4 weeks

  3. In-hospital mortality

    Mortality rates for the entire period of hospitalization

    Time frame: up to 4 weeks

  4. 90-day readmission rate

    Percentage of readmission to hospital within 90 days of study inclusion

    Time frame: up to 4 weeks

  5. Infection complications

    Pulmonary infection, urinary tract infection, bloodstream infections, etc

    Time frame: up to 4 weeks

  6. Acute physiology and chronic health evaluation (APACHE) Ⅱ score

    0-67, higher scores correspond to more severe disease and a higher risk of death

    Time frame: 0h after study inclusion

  7. Acute physiology and chronic health evaluation (APACHE) Ⅱ score

    0-67, higher scores correspond to more severe disease and a higher risk of death

    Time frame: 24 hours after study inclusion

  8. Acute physiology and chronic health evaluation (APACHE) Ⅱ score

    0-67, higher scores correspond to more severe disease and a higher risk of death

    Time frame: 48 hours after study inclusion

  9. Acute physiology and chronic health evaluation (APACHE) Ⅱ score

    0-67, higher scores correspond to more severe disease and a higher risk of death

    Time frame: 72 hours after study inclusion

  10. Sequential organ failure assessment (SOFA) score

    0-43, higher scores correspond to more severe sepsis

    Time frame: 0 hour after study inclusion

  11. Sequential organ failure assessment (SOFA) score

    0-43, higher scores correspond to more severe sepsis

    Time frame: 24 hours after study inclusion

  12. Sequential organ failure assessment (SOFA) score

    0-43, higher scores correspond to more severe sepsis

    Time frame: 48 hours after study inclusion

  13. Sequential organ failure assessment (SOFA) score

    0-43, higher scores correspond to more severe sepsis

    Time frame: 72 hours after study inclusion

  14. Plasma cytokine levels

    IL-2、IL-4、IL-6、IL-10、IL-17A、IFN-γ、TNF-α

    Time frame: 0 hour after study inclusion

  15. Plasma cytokine levels

    IL-2、IL-4、IL-6、IL-10、IL-17A、IFN-γ、TNF-α

    Time frame: 24 hours after study inclusion

  16. Plasma cytokine levels

    IL-2、IL-4、IL-6、IL-10、IL-17A、IFN-γ、TNF-α

    Time frame: 48 hours after study inclusion

  17. Plasma cytokine levels

    IL-2、IL-4、IL-6、IL-10、IL-17A、IFN-γ、TNF-α

    Time frame: 72 hours after study inclusion

  18. Peripheral blood PMN-MDSC levels

    Frequencies and absolute numbers of total PMN-MDSCs (CD45⁺ CD11b⁺ CD15⁺ CD14- CD33⁺ HLA-DRˡᵒʷ) and the CXCR2⁺ PD-L1⁺ PMN-MDSC subpopulation, assessed via flow cytometry.

    Time frame: Within 72 hours of sepsis diagnosis or ICU admission.

07

Study locations

1 of 1 sites recruiting
  • Department of Critical Care Medicine, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
    Wuhan, Hubei 430022, China
    Recruiting
    • Jiancheng Zhang, Dr. · Contactzhjcheng1@126.com · +8613554105815
    • Jiancheng Zhang, Dr. · Principal investigator
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Sep 2023 (actual). Primary completion is estimated for Oct 2026, 37 months after the start.

Of 496 non-industry observational studies under Sepsis, half reached primary completion within 28 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 57. This study's planned 37 months is above that.

Counting every sponsor, half of 548 studies reached it within 27 months; a quarter within 12 and three quarters within 55.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 13, 2026: primary completion Aug 2026 → Oct 2026 and completion Sep 2026 → Nov 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
May 4, 2023
First posted
May 25, 2023
StartActual
Sep 6, 2023
Primary completionEst.
Oct 30, 2026was Aug 2026
CompletionEst.
Nov 30, 2026was Sep 2026
Last update
Oct 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Primary completion
Aug 31, 2026→Oct 30, 2026
Oct 13, 2026
Study completion
Sep 30, 2026→Nov 30, 2026
Oct 13, 2026
Show all 1 update
  1. Oct 13, 2026
    Primary completion Aug 31, 2026→Oct 30, 2026
    Study completion Sep 30, 2026→Nov 30, 2026

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT05875740
Responsible party
Sponsor
First posted
May 25, 2023
Start date
Sep 6, 2023
Primary completion
Oct 30, 2026 (estimated)
Completion
Nov 30, 2026 (estimated)
Last update
Oct 13, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion